Related Experiment Video
Updated: Feb 27, 2026
10:38
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
Published on: February 1, 2020
8.0K
[R1 resection for pancreatic carcinoma].
G F Weber1, S Kersting2, F Haller3
1Chirurgische Klinik, Universitätsklinikum Erlangen, Krankenhausstraße 12, 91054, Erlangen, Deutschland. georg.weber@uk-erlangen.de.
Summary
Achieving negative resection margins (R0) in pancreatic cancer surgery is crucial for survival. While R1 margins impact outcomes, re-resection and new neoadjuvant/adjuvant therapies can improve results for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Surgical Oncology
- Gastroenterology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) surgery offers the only potential cure.
- Negative (R0) resection margins are critical but not always achievable.
Purpose of the Study:
- To evaluate the impact of R1 resection margins on survival.
- To explore treatment options for intraoperative and postoperative R1 margins in PDAC.
Main Methods:
- Analysis of surgical outcomes for R1 resection margins.
- Review of re-resection techniques and multimodal treatment strategies.
- Assessment of neoadjuvant and adjuvant therapy impacts on PDAC resectability and outcomes.
Main Results:
- Intraoperative R1 margins may be addressed with re-resection, including complex vascular or multi-organ procedures.
- Advanced neoadjuvant and adjuvant treatments enhance PDAC resectability and improve outcomes for R0/R1 resections.
- Arterial resections and additional organ resections are feasible in select cases.
Conclusions:
- R0 resection is the primary surgical goal for PDAC due to the poor prognosis associated with R1 resections.
- Multimodal approaches and re-resection strategies can improve outcomes for patients with R1 margins.
